mRNA Therapeutics for Propionic Acidemia via Lipid Nanoparticle Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no approved drug that directly addresses the underlying enzymatic defect of propionic acidemia, a rare metabolic disorder caused by a deficiency in propionyl-CoA carboxylase, leading to significant morbidity and mortality, with current treatments focusing on dietary interventions and supportive care rather than enzyme replacement.
Innovation Solution
The development of mRNA therapeutics that deliver mRNAs encoding human propionyl-CoA carboxylase alpha and beta subunits via lipid nanoparticles for intracellular synthesis, aiming to increase PCC enzyme activity in patients with propionic acidemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary interventions and supportive care are used to treat propionic acidemia, then patient management is simplified and current treatment protocols are maintained, but the underlying enzymatic defect is not addressed and morbidity and mortality remain significant
Solution Approach 1:
The patent replaces conventional dietary management with mRNA therapy that directly addresses the enzymatic defect. The mRNA therapeutics encode propionyl-CoA carboxylase alpha and beta subunits, enabling de novo synthesis of functional enzyme subunits within patient cells, thereby restoring PCC activity and eliminating the need for complex dietary restrictions
Solution Approach 2:
The patent changes the fundamental parameter of treatment from indirect dietary management to direct enzyme replacement at the molecular level. By administering mRNA that codes for functional PCCA and PCCB subunits, the therapy directly modifies the enzymatic parameter that is defective in propionic acidemia, transforming the treatment paradigm
2Reliability
If mRNA therapeutics are administered to increase PCC enzyme activity, then the underlying enzymatic defect is directly addressed and enzyme activity is restored, but the complexity of delivering and synthesizing functional enzyme subunits increases
Solution Approach 1:
The patent uses mRNA as a copy of the genetic information needed to produce functional enzyme subunits. Instead of delivering complex protein structures directly, the therapy provides a simplified nucleic acid template that cells can readily translate into functional PCCA and PCCB subunits, easing the manufacturing complexity
Solution Approach 2:
The patent leverages the patient's own cellular machinery to produce the therapeutic enzyme subunits. The administered mRNA is taken up by cells and translated using the cell's ribosomes and translation machinery, eliminating the need for external protein production systems and simplifying therapeutic manufacturing
3Ease of operation
If lipid nanoparticles are used to deliver mRNAs intracellularly, then targeted delivery and de novo synthesis of functional proteins is achieved, but the complexity of nanoparticle formulation and intracellular delivery mechanisms increases
Solution Approach 1:
The patent uses lipid nanoparticles as an intermediary carrier to bridge the gap between external mRNA administration and intracellular protein synthesis. The nanoparticles facilitate efficient delivery of mRNA into cells while managing the complexity through a well-established delivery platform that can be optimized for specific tissue targets
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mRNA therapeutics effectively reduce biomarker levels, decrease frequency and duration of metabolic decompensation events, improve cardiac and renal function, and enhance quality of life by increasing PCC enzyme activity, offering a potential cure for the disorder.
Implementation Method 1
The mRNA therapeutics of the invention are particularly well-suited for the treatment of propionic acidemia as the technology provides for the intracellular delivery of mRNAs encoding a human propionyl-CoA carboxylase alpha (PCCA) polypeptide and a human propionyl-CoA carboxylase beta (PCCB) polypeptide
Implementation Method 2
followed by de novo synthesis of functional PCCA and PCCB polypeptides within target cells
Data Source
AI summary
This disclosure relates to mRNA therapy for the treatment of propionic acidemia. mRNAs for use in the invention, when administered in vivo, encode propionyl-CoA carboxy lase alpha (PCCA) and propionyl-CoA carboxy lase beta (PCCB). mRNA therapies of the disclosure increase and/or restore deficient levels of PCCA and/or PCCB expression and/or activity in subjects.